Software identifies cause of ischemic stroke

Identifying the cause of an ischemic stroke is crucial in preventing a second stroke, but physicians lack the tools to make such a determination. Researchers from Massachusetts General Hospital (MGH) and the MGH Stroke Service have developed software capable of pinpointing such causes.

Published in The Journal of the American Medical Association Neurology, the study tests the Causative Classification of Stroke (CCS) software's ability to review more than 150 possible causes of ischemic stroke. Many patients show symptoms suggesting more than one cause, leading to physicians disagreeing in identifying cause(s).

"This was a much-needed study because, although stroke classifications systems are often used in research and clinical practice, these systems are not always able to produce subtypes with discrete pathophysiological, diagnostic and prognostic characteristics," said Hakan Ay, MD, a vascular neurologist, Martinos Center investigator and senior author. "We found that the CCS-based classifications provided better correlations between clinical and imaging stroke features and were better able to discriminate among stroke outcomes than were two conventional, non-automated classification methods."

The CCS software is able to differentiate between causes by using multiple factors including weeding through multiple causes with clinical and imaging features, considering the number of diagnostic tests and ensuring data is entered consistently.

The study involved an analysis of 1,816 ischemic patient, previously enrolled in two previous MGH studies. CCS was able to identify the cause of ischemic strokes in 20 to 40 percent of patients, which were previously unable to determine, as well as determining the risk of having a second stroke within 90 days. The software was also able to reduce the disagreement time between doctors in identifying the stroke cause from 50 to 20 percent.

"The validity data that have emerged from the current study add to the utility of the software-based approach and highlight once again that careful identification and accurate classification of the underlying etiology is paramount for every patient with stroke," said Ay, who is an associate professor of radiology at Harvard Medical School. "The information the software provides not only is critical for effective stroke prevention but also could increase the chances for new discoveries by enhancing the statistical power in future studies of etiologic stroke subtypes. We estimate that, compared to conventional systems, the use of CCS in stroke prevention trials testing targeted treatments for a particular etiologic subtype could reduce the required sample size by as much as 30 percent."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.